Determining the mode of action of bioactive compounds.
暂无分享,去创建一个
[1] Michelle D. Brazas,et al. Using microarray gene signatures to elucidate mechanisms of antibiotic action and resistance. , 2005, Drug discovery today.
[2] Kayoko Yamada,et al. Screening of cell death genes with a mammalian genome-wide RNAi library. , 2010, Journal of biochemistry.
[3] R. Fleischmann,et al. Whole-genome random sequencing and assembly of Haemophilus influenzae Rd. , 1995, Science.
[4] Anna E Speers,et al. Chemical Strategies for Activity‐Based Proteomics , 2004, Chembiochem : a European journal of chemical biology.
[5] Mike Tyers,et al. Cross-species discovery of syncretic drug combinations that potentiate the antifungal fluconazole , 2011, Molecular systems biology.
[6] Ronald W. Davis,et al. Functional profiling of the Saccharomyces cerevisiae genome , 2002, Nature.
[7] A. Coulson,et al. RNA-Mediated Interference as a Tool for Identifying Drug Targets , 2001, American journal of pharmacogenomics : genomics-related research in drug development and clinical practice.
[8] Ronald W. Davis,et al. Functional characterization of the S. cerevisiae genome by gene deletion and parallel analysis. , 1999, Science.
[9] Piero Fariselli,et al. eSLDB: eukaryotic subcellular localization database , 2006, Nucleic Acids Res..
[10] P. Brown,et al. Drug target validation and identification of secondary drug target effects using DNA microarrays , 1998, Nature Medicine.
[11] R. Andersen,et al. Inhibitors of human indoleamine 2,3-dioxygenase identified with a target-based screen in yeast. , 2006, Biotechnology journal.
[12] Shinsuke Ohnuki,et al. High-Content, Image-Based Screening for Drug Targets in Yeast , 2010, PloS one.
[13] Elizabeth A. Winzeler,et al. Genomic profiling of drug sensitivities via induced haploinsufficiency , 1999, Nature Genetics.
[14] Sean R. Collins,et al. Exploration of the Function and Organization of the Yeast Early Secretory Pathway through an Epistatic Miniarray Profile , 2005, Cell.
[15] Michael J. Keiser,et al. Predicting new molecular targets for known drugs , 2009, Nature.
[16] C. N. Coleman,et al. NS-398, ibuprofen, and cyclooxygenase-2 RNA interference produce significantly different gene expression profiles in prostate cancer cells , 2009, Molecular Cancer Therapeutics.
[17] Minghui Yang,et al. Chemical Genetic Profiling and Characterization of Small-molecule Compounds That Affect the Biosynthesis of Unsaturated Fatty Acids in Candida albicans* , 2009, The Journal of Biological Chemistry.
[18] Joshua LaBaer,et al. Microarray-based method for monitoring yeast overexpression strains reveals small-molecule targets in TOR pathway , 2006, Nature chemical biology.
[19] Victoria Chen,et al. Systematic screens of a Candida albicans homozygous deletion library decouple morphogenetic switching and pathogenicity , 2010, Nature Genetics.
[20] Gary D Bader,et al. Systematic Genetic Analysis with Ordered Arrays of Yeast Deletion Mutants , 2001, Science.
[21] Robert P. St.Onge,et al. The Chemical Genomic Portrait of Yeast: Uncovering a Phenotype for All Genes , 2008, Science.
[22] A. Barabasi,et al. Drug—target network , 2007, Nature Biotechnology.
[23] L. Du,et al. Global fitness profiling of fission yeast deletion strains by barcode sequencing , 2010, Genome Biology.
[24] Michel Roberge,et al. Yeast genome-wide drug-induced haploinsufficiency screen to determine drug mode of action. , 2004, Proceedings of the National Academy of Sciences of the United States of America.
[25] Chao Zhang,et al. An integrated platform of genomic assays reveals small-molecule bioactivities. , 2008, Nature chemical biology.
[26] Charles Boone,et al. Microarray-based target identification using drug hypersensitive fission yeast expressing ORFeome. , 2011, Molecular bioSystems.
[27] Sven Bergmann,et al. A modular approach for integrative analysis of large-scale gene-expression and drug-response data , 2008, Nature Biotechnology.
[28] S. Ōmura,et al. STUDIES ON BACTERIAL CELL WALL INHIBITORS , 1979 .
[29] J. Acker,et al. Brefeldin A acts to stabilize an abortive ARF-GDP-Sec7 domain protein complex: involvement of specific residues of the Sec7 domain. , 1999, Molecular cell.
[30] Corey Nislow,et al. A survey of yeast genomic assays for drug and target discovery. , 2010, Pharmacology & therapeutics.
[31] S. Lindquist,et al. Detection of compounds that rescue Rab1-synuclein toxicity. , 2008, Methods in enzymology.
[32] R. Olsen,et al. Identification of Direct Protein Targets of Small Molecules , 2010, ACS chemical biology.
[33] G. Giaever,et al. Yeast Barcoders: a chemogenomic application of a universal donor-strain collection carrying bar-code identifiers , 2008, Nature Methods.
[34] P. Hergenrother,et al. Transcript profiling and RNA interference as tools to identify small molecule mechanisms and therapeutic potential. , 2011, ACS chemical biology.
[35] B. Cravatt,et al. Activity-based protein profiling: from enzyme chemistry to proteomic chemistry. , 2008, Annual review of biochemistry.
[36] Canguo Zhao,et al. Expression-Based In Silico Screening of Candidate Therapeutic Compounds for Lung Adenocarcinoma , 2011, PloS one.
[37] Corey Nislow,et al. A unique and universal molecular barcode array , 2006, Nature Methods.
[38] T. Golub,et al. Gene expression signature-based chemical genomic prediction identifies a novel class of HSP90 pathway modulators. , 2006, Cancer cell.
[39] S. Lory,et al. Identification of Small Molecule Inhibitors of Pseudomonas aeruginosa Exoenzyme S Using a Yeast Phenotypic Screen , 2008, PLoS genetics.
[40] B. Cravatt,et al. Activity-based protein profiling: the serine hydrolases. , 1999, Proceedings of the National Academy of Sciences of the United States of America.
[41] S H Kim,et al. Exploiting chemical libraries, structure, and genomics in the search for kinase inhibitors. , 1998, Science.
[42] P. Bork,et al. Drug Target Identification Using Side-Effect Similarity , 2008, Science.
[43] Edward W. Tate,et al. Activity-based probes: discovering new biology and new drug targets. , 2011, Chemical Society reviews.
[44] Terry Roemer,et al. Genome-Wide Fitness Test and Mechanism-of-Action Studies of Inhibitory Compounds in Candida albicans , 2007, PLoS pathogens.
[45] Yang Li,et al. PAP inhibitor with in vivo efficacy identified by Candida albicans genetic profiling of natural products. , 2008, Chemistry & biology.
[46] G. P. Smith,et al. Filamentous fusion phage: novel expression vectors that display cloned antigens on the virion surface. , 1985, Science.
[47] Ulrich Schlecht,et al. Gene Annotation and Drug Target Discovery in Candida albicans with a Tagged Transposon Mutant Collection , 2010, PLoS pathogens.
[48] P. Youngman,et al. Mechanism-of-action determination of GMP synthase inhibitors and target validation in Candida albicans and Aspergillus fumigatus. , 2007, Chemistry & biology.
[49] Taro L. Saito,et al. High-dimensional and large-scale phenotyping of yeast mutants. , 2005, Proceedings of the National Academy of Sciences of the United States of America.
[50] R. Kishony,et al. Functional classification of drugs by properties of their pairwise interactions , 2006, Nature Genetics.
[51] Mike Tyers,et al. Off-Target Effects of Psychoactive Drugs Revealed by Genome-Wide Assays in Yeast , 2008, PLoS genetics.
[52] B. Cravatt,et al. Activity-based Proteomics of Enzyme Superfamilies: Serine Hydrolases as a Case Study* , 2010, The Journal of Biological Chemistry.
[53] J. Davies,et al. The world of subinhibitory antibiotic concentrations. , 2006, Current opinion in microbiology.
[54] Elo Leung,et al. Targeted Genome Editing Across Species Using ZFNs and TALENs , 2011, Science.
[55] J. McClure,et al. Transcriptional modulation of bacterial gene expression by subinhibitory concentrations of antibiotics , 2002, Proceedings of the National Academy of Sciences of the United States of America.
[56] E. Brown,et al. Multicopy suppressors for novel antibacterial compounds reveal targets and drug efflux susceptibility. , 2004, Chemistry & biology.
[57] H. Kitano,et al. In Vivo Robustness Analysis of Cell Division Cycle Genes in Saccharomyces cerevisiae , 2006, PLoS genetics.
[58] T. Hughes,et al. Mapping pathways and phenotypes by systematic gene overexpression. , 2006, Molecular cell.
[59] Lani F. Wu,et al. Image-based multivariate profiling of drug responses from single cells , 2007, Nature Methods.
[60] R. Solé,et al. Data completeness—the Achilles heel of drug-target networks , 2008, Nature Biotechnology.
[61] Benjamin F. Cravatt,et al. Activity-based protein profiling for biochemical pathway discovery in cancer , 2010, Nature Reviews Cancer.
[62] Yudong D. He,et al. Functional Discovery via a Compendium of Expression Profiles , 2000, Cell.
[63] A. Klug,et al. Targeted gene knockout in mammalian cells by using engineered zinc-finger nucleases , 2008, Proceedings of the National Academy of Sciences.
[64] B. Spratt. Properties of the penicillin-binding proteins of Escherichia coli K12,. , 1977, European journal of biochemistry.
[65] G. Giaever,et al. Combining chemical genomics screens in yeast to reveal spectrum of effects of chemical inhibition of sphingolipid biosynthesis , 2009, BMC Microbiology.
[66] Jyoti Pande,et al. Phage display: concept, innovations, applications and future. , 2010, Biotechnology advances.
[67] A. Feig,et al. Peptide inhibitors targeting Clostridium difficile toxins A and B. , 2010, ACS chemical biology.
[68] T. Roemer,et al. Isolation, structure elucidation, and biological activity of virgineone from Lachnum Wirgineum using the genome-wide Candida albicans fitness test. , 2009, Journal of natural products.
[69] D. Drubin,et al. A yeast killer toxin screen provides insights into a/b toxin entry, trafficking, and killing mechanisms. , 2009, Developmental cell.
[70] Mike Tyers,et al. Combinations of antibiotics and nonantibiotic drugs enhance antimicrobial efficacy. , 2011, Nature chemical biology.
[71] Jeff Piotrowski,et al. Combining functional genomics and chemical biology to identify targets of bioactive compounds. , 2011, Current opinion in chemical biology.
[72] Corey Nislow,et al. Genome-wide analysis of barcoded Saccharomyces cerevisiae gene-deletion mutants in pooled cultures , 2007, Nature Protocols.
[73] Sandra Tenreiro,et al. Transcriptomic Profiling of the Saccharomyces cerevisiae Response to Quinine Reveals a Glucose Limitation Response Attributable to Drug-Induced Inhibition of Glucose Uptake , 2009, Antimicrobial Agents and Chemotherapy.
[74] Ronald W. Davis,et al. Quantitative phenotypic analysis of yeast deletion mutants using a highly parallel molecular bar–coding strategy , 1996, Nature Genetics.
[75] Liangjiang Wang,et al. Microarray data integration for genome-wide analysis of human tissue-selective gene expression , 2010, BMC Genomics.
[76] Grant W. Brown,et al. Integration of chemical-genetic and genetic interaction data links bioactive compounds to cellular target pathways , 2004, Nature Biotechnology.
[77] Douglas A Lauffenburger,et al. A mammalian functional-genetic approach to characterizing cancer therapeutics. , 2010, Nature chemical biology.
[78] T. Golub,et al. Gene expression-based chemical genomics identifies rapamycin as a modulator of MCL1 and glucocorticoid resistance. , 2006, Cancer cell.
[79] G. Thallinger,et al. YPL.db2: the yeast protein localization database, version 2.0 , 2005, Yeast.
[80] G. Bammert,et al. Discovery and Characterization of QPT-1, the Progenitor of a New Class of Bacterial Topoisomerase Inhibitors , 2008, Antimicrobial Agents and Chemotherapy.
[81] Christoph Freiberg,et al. The impact of transcriptome and proteome analyses on antibiotic drug discovery. , 2004, Current opinion in microbiology.
[82] K. Shaw,et al. Transcriptional profiling and drug discovery. , 2003, Current opinion in pharmacology.
[83] Eric D Brown,et al. Chemical probes of Escherichia coli uncovered through chemical-chemical interaction profiling with compounds of known biological activity. , 2010, Chemistry & biology.
[84] Roy Kishony,et al. Networks from drug–drug surfaces , 2007, Molecular systems biology.
[85] Michael I. Jordan,et al. Chemogenomic profiling: identifying the functional interactions of small molecules in yeast. , 2004, Proceedings of the National Academy of Sciences of the United States of America.
[86] Yixue Li,et al. Gene expression module-based chemical function similarity search , 2008, Nucleic acids research.
[87] Corey Nislow,et al. Combination chemical genetics. , 2008, Nature chemical biology.
[88] Anna Y. Lee,et al. Reverse Genetics in Candida albicans Predicts ARF Cycling Is Essential for Drug Resistance and Virulence , 2010, PLoS pathogens.
[89] E. Brown,et al. Chemical genomics in Escherichia coli identifies an inhibitor of bacterial lipoprotein targeting. , 2009, Nature chemical biology.
[90] Yolanda T. Chong,et al. A picture is worth a thousand words: Genomics to phenomics in the yeast Saccharomyces cerevisiae , 2009, FEBS letters.
[91] Peter G Schultz,et al. A genome-wide overexpression screen in yeast for small-molecule target identification. , 2005, Chemistry & biology.
[92] R. W. Davis,et al. Targeted selection of recombinant clones through gene dosage effects. , 1983, Proceedings of the National Academy of Sciences of the United States of America.
[93] Ian Dunham,et al. A systematic library for comprehensive overexpression screens in Saccharomyces cerevisiae , 2008, Nature Methods.
[94] Inmar E. Givoni,et al. Exploring the Mode-of-Action of Bioactive Compounds by Chemical-Genetic Profiling in Yeast , 2006, Cell.
[95] Corey Nislow,et al. Recent advances and method development for drug target identification. , 2010, Trends in pharmacological sciences.
[96] Gary D Bader,et al. The Genetic Landscape of a Cell , 2010, Science.
[97] Corey Nislow,et al. Yeast chemical genomics and drug discovery: an update. , 2008, Trends in pharmacological sciences.
[98] Shin-ichi Sato,et al. Biochemical target isolation for novices: affinity-based strategies. , 2010, Chemistry & biology.
[99] S. Chandrasegaran,et al. Custom-designed zinc finger nucleases: What is next? , 2007, Cellular and Molecular Life Sciences.
[100] G. Church,et al. A global view of pleiotropy and phenotypically derived gene function in yeast , 2005, Molecular systems biology.
[101] R. Dasgupta,et al. An RNAi-based chemical genetic screen identifies three small-molecule inhibitors of the Wnt/wingless signaling pathway , 2011, Proceedings of the National Academy of Sciences.
[102] Robert P. St.Onge,et al. Genome-Wide Requirements for Resistance to Functionally Distinct DNA-Damaging Agents , 2005, PLoS genetics.
[103] D. Hughes,et al. A vancomycin photoprobe identifies the histidine kinase VanSsc as a vancomycin receptor. , 2010, Nature chemical biology.
[104] Stuart L Schreiber,et al. A small molecule suppressor of FK506 that targets the mitochondria and modulates ionic balance in Saccharomyces cerevisiae. , 2003, Chemistry & biology.
[105] Michael Riffle,et al. The Yeast Resource Center Public Image Repository: A large database of fluorescence microscopy images , 2010, BMC Bioinformatics.
[106] K. Shokat,et al. Chemical Genetics: Where Genetics and Pharmacology Meet , 2007, Cell.
[107] J. Lehár,et al. Multi-target therapeutics: when the whole is greater than the sum of the parts. , 2007, Drug discovery today.
[108] Hinrich W. H. Göhlmann,et al. A Diarylquinoline Drug Active on the ATP Synthase of Mycobacterium tuberculosis , 2005, Science.
[109] Timothy J Mitchison,et al. Small molecule screening by imaging. , 2006, Current opinion in chemical biology.
[110] Y. Ohya,et al. Diversity of Ca2+-Induced Morphology Revealed by Morphological Phenotyping of Ca2+-Sensitive Mutants of Saccharomyces cerevisiae , 2007, Eukaryotic Cell.
[111] Meredith C Henderson,et al. Synthetic lethal RNAi screening identifies sensitizing targets for gemcitabine therapy in pancreatic cancer , 2009, Journal of Translational Medicine.
[112] Filip Pattyn,et al. Meta-mining of Neuroblastoma and Neuroblast Gene Expression Profiles Reveals Candidate Therapeutic Compounds , 2009, Clinical Cancer Research.